首页> 外文期刊>BMC Complementary and Alternative Medicine >Protective effects of Xinji′erkang on myocardial infarction induced cardiac injury in mice
【24h】

Protective effects of Xinji′erkang on myocardial infarction induced cardiac injury in mice

机译:心基尔康对小鼠心肌梗死所致心脏损伤的保护作用

获取原文
       

摘要

Background Myocardial infarction (MI) is a major risk factor responsible for morbidity and mortality. Xinji′erkang (XJEK) has been clinically used as an effective medication in the treatment of coronary heart disease and myocarditis. The purpose of this study was to investigate the cardioprotective effect of Xinji′erkang on MI mice. Methods Forty male mice were randomly assigned into four groups as follows ( n =?10): sham, model, MI with administration of XJEK and fosinopril for four weeks. At the end of studies, hemodynamic parameters and electrocardiography (ECG) were recorded. Heart and body mass were measured and heart weight/body weight (HW/BW) ratio was calculated as index of hypertrophy. The hypertrophy of heart and aorta was examined using the hematoxylin and eosin (HE) staining, and the collagen deposition was evaluated using Van Gieson (VG) staining. Serum nitric oxide level (NO), superoxide dismutase (SOD) activity and malondialdehyde (MDA) concentration were assayed by colorimetric analysis. The expressions of endothelial NO synthetase (eNOS) expression in serum and cardiac tissues were determined using ELISA assay and immunohistochemistry. Angiotensin II (Ang II) in serum and cardiac tissues was measured using ELISA assay. Besides, tumor necrosis factor-α (TNF-α), interleukin1β (IL-1β) and interleukin10 (IL-10) were observed in cardiac tissues with ELISA assay as well. Results The administration of XJEK significantly improved cardiac dysfunction and abnormal ECG with reduced HW/BW ratio and ameliorated cardiomyocyte hypertrophy and collagen deposition compared to MI, which was partly due to the decreased SOD and increased MDA in serum. Moreover, XJEK treatment also improved endothelial dysfunction (ED) with not only enhanced eNOS activities in serum and cardiac tissues and elevated NO levels in serum, but also decreased Ang II content in serum and cardiac tissues. Finally, protein expressions of pro-inflammation cytokines, TNF-α and IL-1β in the cardiac tissues with XJEK treatment were significantly decreased compared to model. On the contrary, IL-10, an anti-inflammatory cytokine concentrated in cardiac tissues was significantly enhanced compared to model. Conclusion Xinji′erkang exerts cardioprotective effect on myocardial infarction in mice, which may be due to the improvement of endothelial dysfunction and the reduction of oxidative stress and inflammation response.
机译:背景技术心肌梗塞(MI)是导致发病和死亡的主要危险因素。 Xinji'erkang(XJEK)在临床上已被用作治疗冠心病和心肌炎的有效药物。这项研究的目的是研究辛吉尔康对MI小鼠的心脏保护作用。方法40只雄性小鼠随机分为四组,每组10只,分别为假手术,模型,心肌梗死,XJEK和福辛普利治疗,共4周。在研究结束时,记录了血流动力学参数和心电图(ECG)。测量心脏和体重,并计算心脏重量/体重(HW / BW)比作为肥大指数。使用苏木精和曙红(HE)染色检查心脏和主动脉肥大,并使用Van Gieson(VG)染色评估胶原沉积。用比色法检测血清一氧化氮水平(NO),超氧化物歧化酶(SOD)活性和丙二醛(MDA)浓度。用ELISA法和免疫组化法测定血清和心脏组织中内皮NO合成酶(eNOS)的表达。使用ELISA测定法测量血清和心脏组织中的血管紧张素II(Ang II)。 ELISA法还观察到心脏组织中肿瘤坏死因子-α(TNF-α),白细胞介素1β(IL-1β)和白细胞介素10(IL-10)。结果与MI相比,XJEK的使用显着改善了心脏功能障碍和心电图异常,降低了HW / BW比率,改善了心肌肥大和胶原沉积,部分原因是血清中的SOD降低和MDA升高。此外,XJEK治疗还改善了内皮功能障碍(ED),不仅增强了血清和心脏组织中的eNOS活性,提高了血清中的NO水平,还降低了血清和心脏组织中的Ang II含量。最后,与模型相比,XJEK处理后心脏组织中促炎细胞因子,TNF-α和IL-1β的蛋白表达明显降低。相反,与模型相比,IL-10(一种集中在心脏组织中的抗炎细胞因子)显着增强。结论辛集尔康对小鼠心肌梗死具有心脏保护作用,可能是由于内皮功能障碍的改善,氧化应激和炎症反应的减少所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号